ElevateBio

Powering the creation of cell & gene therapies at a speed the world deserves.

Elevated Insights

From gene editing to biomanufacturing, learn more about the cell and gene therapy industry from our team of industry-leading experts

Featured Insights

// Jul 2026

Rapid Release Testing Starts With Faster Contaminant Detection

By: Gary Sommerville Ph.D., Principal Scientist, NGS, Technical Services

View Insight

// Jul 2026

The Next Base Editors Will Be Engineered, Not Found

By, Matt Nethery, Principal Data Scientist, Computational Biology

View Insight

// Jul 2026

What Makes a Base Editor Potent and Specific Enough for Therapeutic SNP Correction?

By, Sean Crosson, Senior Scientist, Translational Biology

View Insight

// Jul 2026

Scaling Advanced Therapies and U.S. Biomanufacturing

View Insight

// Feb 2025

Accelerating Innovative Cell Therapy Development Through Phase-Appropriate Potency Control

By Deb Bhattacharya, Ph.D., and Cindy Riggins, Ph.D., ElevateBio

View Insight

// Sep 2024

Introducing ElevateBio’s Emerging Technology Lab

By Mercedes Segura, PhD, VP, Process Development, ElevateBio BaseCamp

View Insight

// Sep 2024

How ElevateBio is using AI to expand the therapeutic boundaries of CRISPR

By Shaorong (Ron) Chong, Ph.D., VP of Technology Development, and Joel Parker, Ph.D., VP of Computational Biology, Life Edit Therapeutics

View Insight

// Aug 2024

The complexities of tomorrow’s cell therapies: The future is gene editing

By Mitch Finer, Ph.D., Co-Founder of ElevateBio, former Chief Executive Officer of Life Edit Therapeutics, and Current Strategic Advisor to ElevateBio and Life Edit

View Insight

// Jul 2024

The Future of Manufacturing and Medicine Rising in Pittsburgh’s Hazelwood Green

By Mario Miele, SVP, Facilities and Engineering, ElevateBio

View Insight

// Jun 2024

How ElevateBio’s Foundry Model is Changing the Future of Genetic Medicines

By David Hallal, Chairman and CEO, ElevateBio

View Insight

// Nov 2023

A new chapter in gene editing: The diversity, versatility, and coolness of Life Edit’s technologies

By Hui-Chia Yu-Kemp and Drew Kelso, Technology Development Scientists, Life Edit Therapeutics, an ElevateBio company

View Insight

// Oct 2023

Biotechnology: The Key to America’s Next Manufacturing Revolution

By Heidi Wagner, Global Head of Government Affairs, and Mike Paglia, Chief Operating Officer of ElevateBio BaseCamp

View Insight

// Aug 2023

Partner Case Study: Accelerating Treg Therapy Manufacturing

By ElevateBio and Abata Therapeutics

View Insight

// Jan 2023

Reflecting on ElevateBio’s First Five Years

From our Chairman and CEO, David Hallal

View Insight

// Nov 2022

ElevateBio’s Lentiviral Vector Platform: Right the first time

By: Mercedes Segura, Vice President, Process Development, ElevateBio, Dawn Maier, Vice President, Emerging Technologies, ElevateBio, and Bojiao Yin, Director of Vector Process Development, ElevateBio

View Insight

// Nov 2022

The Medicines of Tomorrow: A primer on the gene editing landscape

By Adrian Oliver, Ph.D., Senior Scientist of Technology Development, Life Edit Therapeutics

View Insight

MENU